Abstract
The SARS-CoV-2 B.1.617 variant emerged in the Indian state of Maharashtra in late 2020. There have been fears that 2 key mutations seen in the receptor-binding domain, L452R and E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity.
Highlights
BioResource COVID-19 Collaboration, The Indian SARSCoV-2 Genomics Consortium (INSACOG); Agarwal, Anurag; Ozono, Seiya; Tokunaga, Kenzo; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato, Kei; Gupta, Ravindra K
The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone
B.1.617.1 has 3 key spike mutations, L452R, E484Q, and P681R, whereas B.1.617.2 is characterized by L452R, T478K, and P681R
Summary
BioResource COVID-19 Collaboration, The Indian SARSCoV-2 Genomics Consortium (INSACOG); Agarwal, Anurag; Ozono, Seiya; Tokunaga, Kenzo; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sato, Kei; Gupta, Ravindra K. BioResource COVID-19 Collaboration, Indian SARS-CoV-2 Genomics Consortium, Anurag Agarwal, Seiya Ozono, Kenzo Tokunaga, The Genotype to Phenotype. E484Q, would have additive effects on evasion of neutralizing antibodies. We report that spike bearing L452R and E484Q confers modestly reduced sensitivity to BNT162b2 mRNA vaccine-elicited antibodies following either first or second dose. The effect is similar in magnitude to the loss of sensitivity conferred by L452R or E484Q alone. These data demonstrate reduced sensitivity to vaccine-elicited neutralizing antibodies by L452R and E484Q but lack of synergistic loss of sensitivity
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
